European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976—1996
- 1 May 1998
- Vol. 51 (5) , 50-57
- https://doi.org/10.1016/s0090-4295(98)00076-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Liarozole (R75251) in hormone-resistant prostate cancer patientsThe Prostate, 1997
- High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary GroupEuropean Journal Of Cancer, 1995
- The Final Analysis of the EORTC Genito-Urinary T ract Cancer Co-Operative Group Phase III Clinical Trial (Protocol 30805) Comparing Orchidectomy, Orchidectomy plus Cyproterone Acetate and Low Dose Stilboestrol in the Management of Metastatic Carcinoma of the ProstateEuropean Urology, 1995
- Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)Journal of Urology, 1993
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Multivariate Analysis of Prognostic Factors in Patients with Advanced Prostatic Cancer: Results from 2 European Organization for Research on Treatment of Cancer TrialsJournal of Urology, 1989
- A Comparison of the Effect of Diethylstilbestrol with Low Dose Estramustine Phosphate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Phase III Trial of the European Organization for Research on Treatment of CancerJournal of Urology, 1986
- Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urological GroupJournal of Urology, 1986
- Treatment response criteria for prostatic cancerThe Prostate, 1984
- New Hormonal Therapy in Prostate Cancer: Combined Use of a Pure Antiandrogen and an LHRH AgonistHormone Research, 1983